Forecast

There is no analyst data available for this company.

News Go to news feed

Advanced Medical Solutions extends deadline for H.B. Fuller to 2 July

Advanced Medical Solutions has extended the “put up or shut up” deadline for H.B. Fuller to 2 July 2026 at 17:00 London time. The Takeover Panel approved the extension; the original deadline expired today. The parties continue to hold talks, no firm offer has been confirmed, and the AMS board is advising shareholders to take no action for now. » More on de.investing.com
Advanced Medical Solutions invites shareholders to annual general meeting on 17 June

Advanced Medical Solutions has sent its annual report and financial statements for the year ended 31 December 2025, together with the invitation to the annual general meeting, to shareholders. The AGM will be held on 17 June 2026 at 11:00 in the offices of Investec Bank, 30 Gresham Street, London. The annual report, financial statements and proxy form are available in the investor relations section of the company's website. » More on de.investing.com
Advanced Medical Solutions: 2025 annual results in line with guidance with strong Surgical growth

Advanced Medical Solutions reported 2025 revenue of £228.9m and adjusted EBITDA of £49.9m (adjusted EBITDA margin 21.8%), in line with the January update and analyst consensus. The Surgical division grew 36% at constant currency and was a major contributor; Woundcare rose 9% at constant currency. Margins were 24.4% (Surgical) and 13.6% (Woundcare); EPS came in 3% below the FactSet consensus due to higher interest expenses. Synergies from the acquisitions of Peters and Syntacoll are progressing as planned, and the company expects 2026 revenue and EBITDA to be in line with market expectations, with strong cash generation to reduce debt. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Advanced Medical Solutions has already paid €0.0309 in dividends. The last payout was in October 2025.

Financials

In the last quarter, Advanced Medical Solutions had revenue of €135.44M and net profit of €4.3M

(EUR)	Dec 2025	YoY
Revenue	135.44M	-
Gross profit	64.51M	-
Net profit	4.3M	-
EBITDA	25.57M	-

Fundamentals

Metric	Value
Market capitalization	€713M
Number of shares	216.4M
52-week high/low	€3.32 - €2.18
Dividend yield	0.30%
Dividends TTM	€0.00973
Beta	0.70
P/E ratio	61.04
PEG ratio	1.51
P/B ratio	2.36
P/S ratio	2.67

Company profile

Advanced Medical Solutions Group plc entwirft, entwickelt, produziert und vertreibt zusammen mit ihren Tochtergesellschaften Produkte für die Wundversorgung, die Chirurgie und den Wundverschluss im Vereinigten Königreich, Deutschland, Frankreich, dem übrigen Europa, den Vereinigten Staaten und international. Das Unternehmen ist in zwei Segmenten tätig: Chirurgie und Wundversorgung. Das Segment Chirurgie bietet unter der Marke LiquiBand topische Gewebeklebstoffe für den Wundverschluss und die Versiegelung, unter der Marke RESORBA Nahtmaterial und Produkte auf Kollagenbasis für den chirurgischen und zahnmedizinischen Markt, Kollagene und laparoskopische Geräte zur Fixierung von im Körperinneren platzierten Herniennetzen unter der Marke LiquiBand Fix8 sowie interne Versiegelungen unter der Marke Seal-G/Seal-G MIST. Das Segment Wundversorgung bietet Plattformtechnologien für die Wundversorgung an, die Alginate, Schäume, Filme, Fasern, Hydrogele, antimikrobielle Verbände und Hydrokolloide sowie Wundversorgungsprodukte unter der Marke ActivHeal umfassen. Die Advanced Medical Solutions Group plc wurde 1991 gegründet und hat ihren Hauptsitz in Winsford, Vereinigtes Königreich.